EUVIMEDObjevte EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes

Matthew Kubina iD, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul iD, Jake P Mann, Eric Trépo, Stephan Buch, Daniel Q Huang iD, Cheng Han Ng iD and 4 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70256 ↗

At a glance

Metaanalyse in Alimentary Pharmacology & Therapeutics, 2025. Written by Matthew Kubina and 15 co-authors. Institution: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Major MEDLINE topics: Fatty Liver, Genetic Predisposition to Disease. Cited 21 times so far (Crossref); 83 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS, Singapore Ministry of Health's National Medical Research Council, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Genetic variants associated with risk of steatotic liver disease (SLD) may also influence clinical events.

Aims

To perform a systematic review and meta‐analysis to determine the impact of SLD‐associated genetic variants on hepatic and extrahepatic complications in SLD.

Methods

We searched PubMed, Embase and Medline databases from inception through July 4th, 2024 for studies on adults with SLD that reported effects of PNPLA3 , TM6SF2 , MBOAT7 , HSD17B13 and GCKR variants on the incidence of cirrhosis, major adverse liver outcomes (MALO), cardiovascular disease, extrahepatic malignancy and overall or cause‐specific mortality. We pooled hazard ratios and 95% confidence intervals from these outcomes to allow for comparison.

Results

We screened 6475 studies and included 40 in the final analysis. PNPLA3 ‐rs738409‐GG genotype (vs. CC genotype) was associated with significantly higher incidence of MALO (sHR 2.30 [95% CI 1.66–3.18]), liver‐related mortality (sHR 2.83 [95% CI 1.58–5.06]) and all‐cause mortality (HR 1.24 [95% CI 1.04–1.47]). TM6SF2 ‐rs58542926‐CT or TT (vs. CC) genotype was associated with a higher incidence of hepatocellular carcinoma (sHR 2.12 [95% CI 1.66–2.70]). MALO was significantly associated with MBOAT7 ‐rs641738‐TT (vs. CC) genotype (sHR 1.21 [95% CI 1.1–1.33]). Limitations in the literature include inconsistent outcome reporting and distribution of fibrosis stage, and a relative paucity of studies on both alcohol‐associated liver disease and non‐ PNPLA3 genetic variants.

Conclusions

Variants in PNPLA3 , TM6SF2 and MBOAT7 are significantly associated with hepatic outcomes, especially with advanced baseline liver disease, with modest effects on extrahepatic outcomes. Routine genotyping may improve risk stratification in SLD patients with advanced liver disease.

Subjects

MeSH terms (MEDLINE)

Fatty LiverGenetic Predisposition to DiseaseHumansAllelesGenotypeLipaseMembrane ProteinsRisk FactorsAcyltransferasesPhospholipases A2, Calcium-Independent

Author keywords

ALDMASLDcardiovascular diseasesfatty livergenotypehepatocellular carcinomaliver cirrhosisrisk assessment

Substances

LipaseMBOAT7 protein, humanMembrane ProteinsPNPLA3 protein, humanTM6SF2 protein, humanAcyltransferasesPhospholipases A2, Calcium-Independent

Authors and institutions

  • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Singapore General Hospital, Singapore, Singapore.
  • Department of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
  • Liver Unit, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

ORCID profiles: Matthew Kubina, Pojsakorn Danpanichkul, Daniel Q Huang, Cheng Han Ng, Yu Jun Wong, Karn Wijarnpreecha, Vincent L Chen

Funding

  • NIDDK NIH HHS
  • Singapore Ministry of Health's National Medical Research Council
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Kubina, M., Prasitsumrit, V., Tan, J., Quek, J. W. E., Peddu, D., Mishra, A., Danpanichkul, P., Mann, J. P., Trépo, E., Buch, S., Huang, D. Q., Ng, C. H., Muthiah, M. D., Wong, Y. J., Wijarnpreecha, K., & Chen, V. L. (2025). Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70256

Vancouver

Kubina M, Prasitsumrit V, Tan J, Quek JWE, Peddu D, Mishra A, et al. Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70256

BibTeX
@article{Kubina2025,
  author = {Kubina, Matthew and Prasitsumrit, Vitchapong and Tan, Jarell and Quek, Joo Wei Ethan and Peddu, Dhiraj and Mishra, Ankit and Danpanichkul, Pojsakorn and Mann, Jake P and Trépo, Eric and Buch, Stephan and Huang, Daniel Q and Ng, Cheng Han and Muthiah, Mark D and Wong, Yu Jun and Wijarnpreecha, Karn and Chen, Vincent L},
  title = {Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70256}
}
Start for free →